

1 **Supplementary Table 1: Association between types of treatment and the achievement of PR in 85 NSCLC patients.**

2

Types of treatment	N	PR (%)	<i>p</i> -value ¹
<i>Targeted therapy: single agent</i>	50	1 (2)	0.002
<i>Targeted therapy: combinations</i>	14	1 (7)	
<i>Targeted therapy combined with chemotherapy</i>	13	5 (38.5)	
<i>Chemotherapy</i>	8	1 (12.5)	

3

4

5 ¹ *p*-value was based on comparing the proportion of patients with a PR among the four treatment groups (Fisher's exact test).

Supplementary Table 2: The PFS on the first-line therapy, second-line therapy and phase I therapy for advanced/metastatic NSCLC. The median PFS on the first-line therapy was statistically significantly longer than on the second-line and phase I therapies. Also, the median PFS on the second-line therapy was longer than on phase I therapy at borderline statistical significance.

Systemic therapy	Number/Events	Median PFS in months	95% CI	<i>p</i> -value ¹
First-line therapy	73/70	6.1	5.2–7.6	$p = 0.010$ $p = 0.05$ $p < 0.0001$
Second-line therapy	53/50	3.4	2.7–5.4	
Phase I therapy	85/79	2.8	2.4–3.4	

¹ *p*-value by log-rank test.